International Journal of Drug Policy
Volume 21, Issue 3 , Pages 247-250 , May 2010

The reach of a free hepatitis B vaccination programme: Results of a Dutch study among drug users

  • Jessica E. Baars

      Affiliations

    • IVO, Addiction Research Institute, Rotterdam, The Netherlands
    • Department of Public Health, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author at: IVO, Addiction Research Institute, Heemraadssingel 194, 3021 DM, Rotterdam, The Netherlands. Tel.: +31 10 425 33 66; fax: +31 10 276 39 88.
    • ,
  • Brigitte J.F. Boon

      Affiliations

    • IVO, Addiction Research Institute, Rotterdam, The Netherlands
    • ,
  • Henk F.L. Garretsen

      Affiliations

    • Department Tranzo, Faculty of Behavioural and Social Science, University of Tilburg, Tilburg, The Netherlands
    • ,
  • Dike van de Mheen

      Affiliations

    • IVO, Addiction Research Institute, Rotterdam, The Netherlands
    • Department of Public Health, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands

Received 26 February 2009 ,Revised 10 June 2009 ,Accepted 9 July 2009.

References 

  1. Baars JE, Boon B, Garretsen HF, Van de Mheen D. Vaccination uptake and awareness of a free hepatitis B vaccination program among female commercial sex workers. Women's Health Issues. 2009;19:61–69
  2. Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J. Accuracy of perceptions of hepatitis B and C status: Cross sectional investigation of opiate addicts in treatment. British Medical Journal. 1999;19:290–291
  3. Campbell JV, Garfein RS, Thiede H, Hagan H, Ouellet LJ, Golub ET, et al. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug and Alcohol Dependence. 2007;91:S64–72
  4. Des Jarlais DC, Fisher DG, Newman JC, Trubatch BN, Yancovitz M, Paone D, et al. Providing hepatitis B vaccination to injection drug users: Referral to health clinics vs onsite vaccination at a syringe exchange program. American Journal of Public Health. 2001;91:1791–1792
  5. Fishbein M, Pequegnat W. Evaluating AIDS prevention interventions using behavioral and biological outcome measures. Sexually Transmitted Diseases. 2000;27:101–110
  6. Heijnen M, Waldhober Q, Siedenburg E, Al Taqatqa W, Huijsen R, De Vries M. Hepatitis B vaccination project for behavioural risk groups in the Netherlands. Eurosurveillance. 2004;8:2609;Available: http://www.eurosurveillance.org Accessed 6.12.2008
  7. Kuo I, Mudrick DW, Strathdee SA, Thomas DL, Sherman SG. Poor validity of self-reported hepatitis B virus infection and vaccination status among young drug users. Clinical Infectious Diseases. 2004;38:587–590
  8. Langendam MW, Van Haastrecht HJ, Van Ameijden EJ. The validity of drug users’ self-reports in a non-treatment setting: Prevalence and predictors of incorrect reporting methadone treatment modalities. International Journal of Epidemiology. 1999;28:514–520
  9. Muhib FB, Lin LS, Stueve A, Miller RL, Ford WL, Johnson WD, et al. A venue-based method for sampling hard-to-reach populations. Public Health Report. 2001;116:216–222
  10. Schlicting EG, Johnson ME, Brems C, Wells RS, Fisher DG, Reynolds G. Validity of injecting drug users’ self report of hepatitis A, B, and C. Clinical Laboratory Science. 2003;16:99–106
  11. Van Steenbergen JE. Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands (1998–2000) among men who have sex with men, hard drug users, sex workers and heterosexual persons with multiple partners. Journal of Hepatology. 2002;37:507–513
  12. Vincente J, Wiessing L. European Monitoring Centre for Drugs and Drug Addiction annual report 2007: Positive assessment of HIV in IDUs though hepatitis C still very high. Eurosurveillance. 2007;12:3317
  13. Waldhober Q, Heijnen M-L. Landelijk bereik van HBV-vaccinatiecampagne risicogroepen. Infectieziekten Bulletin. 2003;14:249–253
  14. Watters JK, Biernacki P. Targeted sampling: Options for the study of hidden populations. Social Problems. 1989;36:416–430

PII: S0955-3959(09)00108-X

doi: 10.1016/j.drugpo.2009.07.001

International Journal of Drug Policy
Volume 21, Issue 3 , Pages 247-250 , May 2010

Article Tools